Gonadorelin HCl | CAS#51952-41-1 | LUTEINIZING HORMONE

MedKoo Cat#: 598790 | Name: Gonadorelin HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gonadorelin HCl is a decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.

Chemical Structure

Gonadorelin HCl

CAS#51952-41-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 598790

Name: Gonadorelin HCl

CAS#: 51952-41-1 (HCl)

Chemical Formula: C55H76ClN17O13

Exact Mass: 0.0000

Molecular Weight: 1218.76

Elemental Analysis: C, 54.20; H, 6.29; Cl, 2.91; N, 19.54; O, 17.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

34973-08-5 (acetate) 33515-09-2 (free base) 51952-41-1 (HCl) 499785-55-6(monoacetate) 78308-49-3 (diacetate hydrate) 71447-49-9 (diacetate)

Synonym

Gonadorelin hydrochloride; Gonadorelin HCl; AY-24,031; AY 24,031; AY24,031; Factrel; LH-RH hydrochloride;

IUPAC/Chemical Name

(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;hydrochloride

InChi Key

UPRWQSQENCASAD-HBBGHHHDSA-N

InChi Code

InChI=1S/C55H75N17O13.ClH/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36;/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60);1H/t36-,37-,38-,39-,40-,41-,42-,43-;/m0./s1

SMILES Code

O=C(N)CNC([C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC(CNC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CO)NC([C@H](CC3=CNC4=C3C=CC=C4)NC([C@H](CC5=CNC=N5)NC([C@H](CC6)NC6=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,218.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Li CX, Tang ST, Zhang Q. Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism. Int J Endocrinol. 2015;2015:324524. doi: 10.1155/2015/324524. Epub 2015 Aug 31. PubMed PMID: 26417369; PubMed Central PMCID: PMC4568382. 2: Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1387-9. doi: 10.1515/jpem-2015-0183. PubMed PMID: 26197466. 3: Poock SE, Lamberson WR, Lucy MC. Effect of different gonadorelin (GnRH) products used for the first or resynchronized timed artificial insemination on pregnancy rates in postpartum dairy cows. Theriogenology. 2015 Sep 1;84(4):504-8. doi: 10.1016/j.theriogenology.2015.04.002. Epub 2015 Apr 14. PubMed PMID: 25979657. 4: Picard-Hagen N, Lhermie G, Florentin S, Merle D, Frein P, Gayrard V. Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology. 2015 Jul 15;84(2):177-83. doi: 10.1016/j.theriogenology.2015.03.004. Epub 2015 Mar 14. PubMed PMID: 25890780. 5: Fu JF, Liang JF, Zhou XL, Prasad HC, Jin JH, Dong GP, Rose SR. Impact of BMI on gonadorelin-stimulated LH peak in premenarcheal girls with idiopathic central precocious puberty. Obesity (Silver Spring). 2015 Mar;23(3):637-43. doi: 10.1002/oby.21010. Epub 2015 Feb 3. PubMed PMID: 25645648. 6: Freick M, Weber O, Passarge O, Neubert T. [Use of gonadorelin[6-D-Phe] at day 0 or 12 after insemination to increase the conception rate in a large dairy herd in Saxony/Germany]. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2014;42(6):331-42. doi: 10.15653/TPG-140315. Epub 2014 Nov 17. German. PubMed PMID: 25401927. 7: Shao WM, Bai WJ, Chen YM, Liu L, Wang YJ. [Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review]. Beijing Da Xue Xue Bao. 2014 Aug 18;46(4):642-5. Review. Chinese. PubMed PMID: 25131486. 8: Janakiram NB, Mohammed A, Brewer M, Bryant T, Biddick L, Lightfoot S, Pathuri G, Gali H, Rao CV. Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila). 2014 Mar;7(3):300-9. doi: 10.1158/1940-6207.CAPR-13-0345. Epub 2014 Jan 15. PubMed PMID: 24431404; PubMed Central PMCID: PMC3951612. 9: Shanehsazzadeh S, Lahooti A, Sadeghi HR, Jalilian AR. Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data. Nucl Med Commun. 2011 Jan;32(1):37-43. doi: 10.1097/MNM.0b013e328340b916. PubMed PMID: 21068688. 10: Souza AH, Cunha AP, Silva EP, Gümen A, Ayres H, Guenther JN, Wiltbank MC. Comparison of gonadorelin products in lactating dairy cows: efficacy based on induction of ovulation of an accessory follicle and circulating luteinizing hormone profiles. Theriogenology. 2009 Jul 15;72(2):271-9. doi: 10.1016/j.theriogenology.2009.02.016. Epub 2009 Apr 24. PubMed PMID: 19394072. 11: Hoogeveen J, Van der Veer E. Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia. J Sex Med. 2008 Mar;5(3):626-30. Epub 2007 Oct 30. PubMed PMID: 17971105. 12: Brüssow KP, Kanitz E, Tuchscherer A, Tosch P. Study of enteral versus parenteral application of the gonadotropin releasing hormone agonist Gonadorelin[6-D-Phe] (D-Phe6-LHRH) on LH secretion in Goettinger miniature pigs. J Reprod Dev. 2007 Jun;53(3):699-706. Epub 2007 Mar 14. PubMed PMID: 17380039. 13: Hoogeveen JH, van der Veer E. [Side effects of treatment with the long-acting gonadorelin agonist triptorelin in a case of paraphilia]. Tijdschr Psychiatr. 2007;49(2):111-5. Dutch. PubMed PMID: 17290340. 14: Bouchard P. [Gonadorelin antagonists: present and future ]. Rev Prat. 2005;Spec. No:25-7. Review. French. PubMed PMID: 15822867. 15: Jiang YJ, Liang L, Zhouliang ZC, Fu JF, Li Y, Hong F, Dong GP. [Simplified gonadorelin stimulation test in diagnosis of precocious puberty]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004 Sep;33(5):452-5. Chinese. PubMed PMID: 15476332. 16: Rastegarnia A, Niasari-1: Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1387-9. doi: 10.1515/jpem-2015-0183. PubMed PMID: 26197466. 2: Kesler DJ, Summers RN, Peterson CA, Steckler TL. Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine. Drug Dev Ind Pharm. 1999 Mar;25(3):315-21. PubMed PMID: 10071824. 3: Souza AH, Cunha AP, Silva EP, Gümen A, Ayres H, Guenther JN, Wiltbank MC. Comparison of gonadorelin products in lactating dairy cows: efficacy based on induction of ovulation of an accessory follicle and circulating luteinizing hormone profiles. Theriogenology. 2009 Jul 15;72(2):271-9. doi: 10.1016/j.theriogenology.2009.02.016. Epub 2009 Apr 24. PubMed PMID: 19394072. 4: Wong W, Mercorelli M, DeLuccia F, Young R, Lane PA, Hoerig J, Turan A. Stability and purity profile of gonadorelin acetate: a high-purity gonadotropin-releasing hormone. Int J Fertil. 1990 Sep-Oct;35(5):302-9. PubMed PMID: 1980667. 5: Assumpção AA, Garcia FD, Garcia HD, Bradford JM, Thibaut F. Pharmacologic treatment of paraphilias. Psychiatr Clin North Am. 2014 Jun;37(2):173-81. doi: 10.1016/j.psc.2014.03.002. Epub 2014 Apr 18. Review. PubMed PMID: 24877704. 6: Shanehsazzadeh S, Lahooti A, Sadeghi HR, Jalilian AR. Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data. Nucl Med Commun. 2011 Jan;32(1):37-43. doi: 10.1097/MNM.0b013e328340b916. PubMed PMID: 21068688. 7: Cordeddu L, Bergvall M, Sand E, Roth B, Papadaki E, Li L, D'Amato M, Ohlsson B. Severe gastrointestinal dysmotility developed after treatment with gonadotropin-releasing hormone analogs. Scand J Gastroenterol. 2015 Mar;50(3):291-9. doi: 10.3109/00365521.2014.958098. Epub 2015 Jan 16. PubMed PMID: 25592315. 8: Chinese Society of Reproductive Medicine, Chinese Medical Association. [Using of gonadotropin releasing hormone antagonist protocol: a committee opinion]. Zhonghua Fu Chan Ke Za Zhi. 2015 Nov;50(11):805-9. Chinese. PubMed PMID: 26887765. 9: Iremonger KJ, Herbison AE. Multitasking in Gonadotropin-Releasing Hormone Neuron Dendrites. Neuroendocrinology. 2015;102(1-2):1-7. doi: 10.1159/000368364. Epub 2014 Oct 3. PubMed PMID: 25300776. 10: Yonezawa T, Watanabe A, Kurusu S, Kawaminami M. Gonadotropin-releasing hormone is prerequisite for the constitutive expression of pituitary annexin A5. Endocr J. 2015;62(12):1127-32. doi: 10.1507/endocrj.EJ15-0410. Epub 2015 Oct 3. PubMed PMID: 26440525. 11: Viardot-Foucault V, Nadarajah S, Lye WK, Tan HH. GnRH antagonist pre-treatment: one centre's experience for IVF-ICSI cycle scheduling. Reprod Biomed Online. 2015 Apr;30(4):366-72. doi: 10.1016/j.rbmo.2014.11.018. Epub 2014 Dec 24. PubMed PMID: 25684093. 12: Dolińska B, Ryszka F, Szulc B. Bioavailability of buserelin and gonadorelin in suspensions. Boll Chim Farm. 1995 Sep;134(8):459-60. PubMed PMID: 7576445. 13: Hoitink MA, Beijnen JH, Boschma MU, Bult A, van der Houwen OA, Wiese G, Underberg WJ. Degradation kinetics of three gonadorelin analogues: developing a method for calculating epimerization parameters. Pharm Res. 1998 Sep;15(9):1449-55. PubMed PMID: 9755899. 14: Pace JN, Miller JL, Rose LI. GnRH agonists: gonadorelin, leuprolide and nafarelin. Am Fam Physician. 1991 Nov;44(5):1777-82. PubMed PMID: 1835275. 15: Toumba M, Kokotsis V, Savva SC, Skordis N. Expensive therapies in children: benefit versus cost of combined treatment of recombinant human growth hormone and gonadotropin-releasing hormone analogue in girls with poor height potential. J Pediatr Endocrinol Metab. 2014 Mar;27(3-4):311-6. doi: 10.1515/jpem-2013-0210. PubMed PMID: 24158419. 16: Glanowska KM, Burger LL, Moenter SM. Development of gonadotropin-releasing hormone secretion and pituitary response. J Neurosci. 2014 Nov 5;34(45):15060-9. doi: 10.1523/JNEUROSCI.2200-14.2014. PubMed PMID: 25378170; PubMed Central PMCID: PMC4220034. 17: Vuong TN, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2016 Feb;105(2):356-63. doi: 10.1016/j.fertnstert.2015.10.014. Epub 2015 Oct 31. PubMed PMID: 26523330. 18: Ohlsson B. Gonadotropin-Releasing Hormone and Its Physiological and Pathophysiological Roles in Relation to the Structure and Function of the Gastrointestinal Tract. Eur Surg Res. 2016;57(1-2):22-33. doi: 10.1159/000445717. Epub 2016 Apr 19. Review. PubMed PMID: 27089503. 19: Taneja SS. Re: Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. J Urol. 2014 Apr;191(4):985. doi: 10.1016/j.juro.2014.01.078. Epub 2014 Jan 17. PubMed PMID: 24703121. 20: Sukhbaatar U, Kanasaki H, Mijiddorj T, Oride A, Miyazaki K. Expression of gonadotropin-inhibitory hormone receptors in mouse pituitary gonadotroph LβT2 cells and hypothalamic gonadotropin-releasing hormone-producing GT1-7 cells. Endocr J. 2014;61(1):25-34. Epub 2013 Oct 3. PubMed PMID: 24088662. slaji A, Hovareshti P, Sarhaddi F, Safaei M. The effect of different doses of gonadorelin on ovarian follicle dynamics in river buffalo (Bubalus bubalis). Theriogenology. 2004 Oct 1;62(7):1283-91. PubMed PMID: 15325555. 17: Martínez M, Mapletoft RJ, Kastelic JP, Carruthers T. The effects of 3 gonadorelin products on luteinizing hormone release, ovulation, and follicular wave emergence in cattle. Can Vet J. 2003 Feb;44(2):125-31. PubMed PMID: 12650040; PubMed Central PMCID: PMC340045. 18: Jin XH, Huang WQ. [Research progress in immune regulation of gonadorelin]. Sheng Li Ke Xue Jin Zhan. 2000 Apr;31(2):169-72. Review. Chinese. PubMed PMID: 12545741. 19: Sachyns'ka OV. [Nucleic acid and protein content in rat prostate during combined treatment with the gonadorelin agonist and an androgen receptor inhibitor]. Fiziol Zh. 2001;47(6):30-4. Ukrainian. PubMed PMID: 11962088. 20: Mahe V, Nartowski J, Montagnon F, Dumaine A, Glück N. Psychosis associated with gonadorelin agonist administration. Br J Psychiatry. 1999 Sep;175:290-1. PubMed PMID: 10645342.